Skip to main content
OpenTrials
Completed

NCT Number: NCT04462068

ACE and HLA Genotypes Predict Severity and Disease Progression in Danish Sarcoid Patients

Sarcoidosis is a multisystem granulomatous disease of unknown cause histologically characterized by noncaseating granulomas. Genetic factors affect disease course, which is highly variable and difficult to predict.

This study aims to evaluate the predictive value of ACE and HLA genotypes on disease severity and progression in Danish patients with sarcoidosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcoidosis Hemic and Lymphatic Diseases Hypersensitivity Hypersensitivity, Delayed Immune System Diseases Lymphatic Diseases Lymphoproliferative Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Aarhus University Hospital. Dep. of Respiatory Diseases and Allergology

Aarhus N, 8200, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of sarcoidosis
  • Signed informed consent

Exclusion criteria

  • Inability or unwillingness to adhere to the study
  • Inability to give informed consent

Treatment and study plan

Primary outcomes

  1. Time to initiation of treatment

    Time frame: 1 year from diagnosis

    Time to initiation of systemic immunosuppression for sarcoidosis

Secondary outcomes

  1. Number of participants with extrapulmonary organ involvement

    Time frame: 1 year from diagnosis

    Number of participants diagnosed with extrapulmonary organ involvement

  2. Change in FEV1

    Time frame: 1 year

    Increase/ decline/ no change in FEV1

  3. Change in FVC

    Time frame: 1 year

    Increase/ decline/ no change in FVC

  4. Change in diffusion capacity

    Time frame: 1 year

    Increase/ decline/ no change in diffusion capacity

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Registry information

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Jul 8, 2020
Registry last updated
Jan 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.